Narrative review identifies resistance mechanisms to CDK4/6 inhibitors in estrogen receptor-positive patients, suggesting personalized strategies are needed.
Key resistance mechanisms interfering with CDK4/6 inhibitor efficacy have been identified but are not yet used clinically. Diverse resistance mechanisms observed in individual cases would require individualized approaches to re-sensitize cancer cells and patients to cell cycle inhibition.
No takes yet. Share an insight, caveat, or question.
Stravodimou et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: